Outlook Therapeutics, Inc. (OTLK) Tops Q2 EPS by 9c

Outlook Therapeutics, Inc. (NASDAQ: OTLK) reported Q2 EPS of ($0.89), $0.09 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Outlook Therapeutics, Inc. (OTLK) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Zenas BioPharma (ZBIO) files for up to 7M share offering by selling stockholders
• Hooker Furniture (HOFT) Tops Q2 EPS by 16c, Misses on Revenue